- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04804943
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
Pilot Clinical Study to Investigate the Efficacy and Safety of NOA-001 for the Treatment of Patients With Acute Respiratory Distress Syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
(ARDS caused by Non-COVID-19 cohort): The objectives of this clinical study is to investigate the efficacy and safety of NOA-001 in patients with ARDS caused by Non-COVID-19. The number of patients enrolled is 30 (20 patients in the NOA-001 group and 10 patients in the standard therapy group).
(ARDS caused by COVID-19 cohort): The objectives of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS caused by COVID-19. The number of patients enrolled is 15 (in the NOA-001 group only).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: NOA-001 Team
- Phone Number: +81 3 3245 8588
- Email: clinical-trials.toray.mb@mail.toray
Study Locations
-
-
-
Tokyo, Japan
- Recruiting
- Showa University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
(ARDS caused by Non-COVID-19 cohort)
Inclusion Criteria:
At Informed Consent
Patients with ARDS confirmed by the Berlin definition based on the following diagnostic criteria (a)-(d):
- Patients within 7 days from invasion or exacerbation of respiratory symptoms or acute onset of ARDS.
- Patients with respiratory failure not fully explained by cardiac failure or fluid overload; Need objective assessment (e. g., echo-cardiography) to exclude hydrostatic edema if no risk factor present
- Patients with bilateral opacities not fully explained by effusions, lobar/ lung collapse, or nodules on chest X-ray or CT scan
- Patients with PaO2/ FiO2 ratio ≤ 300 mmHg (PEEP ≥ 5 cmH2O)
- Patients who are intubated and mechanically ventilated
- Patients who can be enrolled in the study within 48 hours after ARDS diagnosis confirmed by Berlin definition
- Patients aged ≥ 16 years at informed consent (Signed informed consent form from legally acceptable representative must be available if patient is aged < 20 years)
At Enrollment
- Patients with PaO2/ FiO2 ratio ≥ 50 mmHg and ≤ 200 mmHg (PEEP ≥ 5 cmH2O)
- Patients with bilateral opacities not fully explained by effusions, lobar/ lung collapse, or nodules on CT scan within 48 hours before enrollment
- Patients who are intubated and mechanically ventilated
- Patients who can be enrolled in the study within 48 hours after ARDS diagnosis confirmed by Berlin definition
Exclusion Criteria:
At Informed Consent
- Patients with mechanical ventilation for more than 48 hours prior to ARDS diagnosis confirmed by Berlin definition
- Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
- Patients who are treated with ECMO or HFOV
- Patients with renal dialysis therapy for chronic renal failure
- Patients with congestive heart failure (NYHA class IV)
- Patients with acuter left ventricular failure
- Patients with liver failure (Child-Pugh grade C)
- Patients who have burns in excess of 15% total body surface area
- Patients after resuscitation from cardiac arrest
- Patients with a history of hypersensitivity to the anticoagulants (Heparin or Nafamostat mesylate)
- Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy within 7 days prior to informed consent
- Patients with pregnancy or lactating
- Patients tested positive for COVID-19
At Enrollment
- Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
- Patients who are treated with ECMO or HFOV after obtaining informed consent prior to enrollment
- Patients with platelet count ≤ 50,000 /mm3 by the latest blood test
- Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy between informed consent and enrollment
- Patients whose life expectancy is ≤ 24 hours after enrollment
- Patients after resuscitation from cardiac arrest between informed consent and enrollment
- Patients tested positive for COVID-19 between informed consent and enrollment
(ARDS caused by COVID-19 cohort)
Inclusion Criteria:
At Informed Consent
- Patients tested positive for COVID-19
Patients with ARDS confirmed by the Berlin definition based on the following diagnostic criteria (a)-(d):
- Patients within 7 days from invasion or exacerbation of respiratory symptoms or acute onset of ARDS.
- Patients with respiratory failure not fully explained by cardiac failure or fluid overload; Need objective assessment (e. g., echo-cardiography) to exclude hydrostatic edema if no risk factor present
- Patients with bilateral opacities not fully explained by effusions, lobar/ lung collapse, or nodules on chest X-ray or CT scan
- Patients with PaO2/ FiO2 ratio ≤ 300 mmHg (PEEP ≥ 5 cmH2O)
- Patients who are intubated and mechanically ventilated
- Patients who can be enrolled in the study within 48 hours after ARDS diagnosis confirmed by Berlin definition
- Patients aged ≥ 16 years at informed consent (Signed informed consent form from legally acceptable representative must be available if patient is aged < 20 years)
At Enrollment
- Patients with PaO2/ FiO2 ratio ≥ 50 mmHg and ≤ 200 mmHg (PEEP ≥ 5 cmH2O)
- Patients who are intubated and mechanically ventilated
- Patients who can be enrolled in the study within 48 hours after ARDS diagnosis confirmed by Berlin definition
Exclusion Criteria:
At Informed Consent
- Patients with mechanical ventilation for more than 48 hours prior to ARDS diagnosis confirmed by Berlin definition
- Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
- Patients who are treated with ECMO or HFOV
- Patients with renal dialysis therapy for chronic renal failure
- Patients with congestive heart failure (NYHA class IV)
- Patients with acuter left ventricular failure
- Patients with liver failure (Child-Pugh grade C)
- Patients who have burns in excess of 15% total body surface area
- Patients after resuscitation from cardiac arrest
- Patients with a history of hypersensitivity to the anticoagulants (Heparin or Nafamostat mesylate)
- Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy within 7 days prior to informed consent
- Patients with pregnancy or lactating
At Enrollment
- Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
- Patients who are treated with ECMO or HFOV after obtaining informed consent prior to enrollment
- Patients with platelet count ≤ 50,000 /mm3 by the latest blood test
- Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy between informed consent and enrollment
- Patients whose life expectancy is ≤ 24 hours after enrollment
- Patients after resuscitation from cardiac arrest between informed consent and enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NOA-001 group (ARDS caused by Non-COVID-19 cohort)
Patients will receive the standard and NOA-001 therapy.
|
NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
|
No Intervention: Standard treatment group (ARDS caused by Non-COVID-19 cohort)
Patients will receive the standard therapy.
|
|
Experimental: NOA-001 group (ARDS caused by COVID-19 cohort)
Patients will receive the standard and NOA-001 therapy.
|
NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilator Free Days (VFD, Days alive and ventilator-free)
Time Frame: Day 28
|
VFD is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFD) within 28 days.
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause Mortality
Time Frame: Up to Day 28, 60 and 90
|
Fatalities, mortality all-causes
|
Up to Day 28, 60 and 90
|
Mortality in ICU
Time Frame: Up to Day 28
|
All-cause mortality for patients who died in Intensive Care Units.
|
Up to Day 28
|
Mortality in Hospital
Time Frame: Up to Day 28
|
The number of patients who died in hospital
|
Up to Day 28
|
Changes in PaO2/ FiO2 ratio
Time Frame: Up to Day 28
|
Up to Day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NOA001ARDS01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
-
Hospices Civils de LyonTerminatedAcute Respiratory Distress Syndrome (ARDS)France
Clinical Trials on NOA-001
-
Isabel Moreno HayCompletedObstructive Sleep ApneaUnited States
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Heartseed Inc.RecruitingHeart Failure | Ischemic Heart DiseaseJapan
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Azura OphthalmicsSyneos Health; Cliantha ResearchCompletedDry Eye | Meibomian Gland DysfunctionCanada, Australia, New Zealand
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Astrogen, Inc.RecruitingAutism Spectrum DisorderKorea, Republic of